Ketamine-assisted therapy works in the brain primarily through blocking NMDA glutamate receptors, which triggers a rapid cascade of downstream effects that restore and enhance synaptic connectivity in brain regions disrupted by depression and other conditions. NMDA receptor blockade activates AMPA receptors and increases the release of brain-derived neurotrophic factor (BDNF), promoting rapid synaptogenesis, the formation of new neural connections in the prefrontal cortex and hippocampus, in circuits that have been reduced in volume and connectivity by chronic depression or trauma. This rapid synaptogenesis produces antidepressant effects within hours to days, unlike traditional antidepressants which require weeks of receptor upregulation through daily dosing before full effects emerge. The neuroplastic changes from ketamine also create a window of enhanced brain adaptability during which psychotherapy can take greater hold, which is why ketamine-assisted therapy integrates medication sessions with structured therapeutic work rather than using ketamine alone. The combined biological and psychological approach produces more durable outcomes than ketamine administered without therapeutic support.

Ketamine-assisted therapy at Moment of Clarity follows three structured phases that together maximize safety, depth, and durability of the treatment. The preparation phase involves one or more sessions before ketamine administration to establish therapeutic rapport, clarify treatment intentions, address any concerns, review the clinical protocol, and ensure psychological readiness for the altered state the medication produces. The administration phase involves the supervised administration of IV ketamine or Spravato in a safe, monitored clinical environment, with trained staff present throughout the session and for the required post-session observation period. The integration phase follows each ketamine session with therapy sessions designed to help patients process the insights, emotional material, and experiences that arose during the ketamine experience and translate them into lasting changes in perspective, behavior, and wellbeing. Research shows that the quality of preparation and integration significantly influences outcomes, and patients who receive all three phases consistently achieve better results than those receiving ketamine without the preparatory and integrative therapeutic components.

Ketamine-assisted therapy is best suited for treatment-resistant depression and major depressive disorder with suicidal ideation, which are the FDA-approved indications for Spravato esketamine and the conditions with the strongest clinical trial evidence for ketamine-based treatment. Patients who have not responded adequately to two or more antidepressant medications of different classes, whose depression has been severely impairing quality of life, or who are in acute distress requiring rapid clinical intervention are the strongest candidates for ketamine-assisted therapy. PTSD, generalized anxiety disorder, and OCD are also treated with ketamine at Moment of Clarity as off-label applications with growing clinical support, particularly when these conditions co-occur with treatment-resistant depression. Substance use disorders show preliminary research support for ketamine's role in breaking compulsive patterns through its neuroplastic mechanism, though this application requires careful clinical evaluation. The pre-treatment evaluation at Moment of Clarity confirms which conditions are most likely to respond to ketamine-assisted therapy in each individual patient's specific clinical situation.

The number of ketamine-assisted therapy sessions needed depends on the form of treatment, the condition being treated, and the individual patient's response. For Spravato, the standard protocol involves twice-weekly sessions for four weeks, once-weekly for four weeks, then maintenance at once every one to two weeks based on response durability. IV ketamine infusion courses for depression typically involve six infusions over two to three weeks as an initial series, followed by maintenance at individualized intervals. For ketamine-assisted psychotherapy using the three-phase preparation, administration, and integration model, the number of sessions per ketamine administration is expanded to include preparation and integration sessions alongside the medication sessions themselves. Patients who receive the full therapeutic model including preparation, integration, and maintenance alongside ongoing psychotherapy consistently achieve more durable outcomes than those receiving fewer sessions. Your clinician at Moment of Clarity will discuss the expected course structure and decision criteria for adjusting session frequency based on your clinical response.

Ketamine-assisted therapy is considered safe when administered by qualified medical professionals in a clinical setting with appropriate patient screening, monitoring, and aftercare, and Moment of Clarity follows all FDA safety protocols and REMS requirements for Spravato and provides full clinical monitoring throughout IV ketamine sessions. Professional supervision is critical because ketamine can cause changes in blood pressure, heart rate, and breathing patterns alongside its psychological effects, and these physiological changes require trained clinical monitoring in real time. The pre-treatment evaluation screens for contraindications including psychosis risk, cardiovascular disease, substance use, and pregnancy, ensuring ketamine is administered only to patients for whom the risk-benefit balance is favorable. Side effects including dissociation, dizziness, and nausea are managed in the clinical setting as they occur. The combination of thorough screening, trained clinical supervision throughout sessions, and structured aftercare makes ketamine-assisted therapy at Moment of Clarity a clinically safe and well-monitored procedure. Call 949-625-0564.

Ketamine-assisted therapy can help when standard therapy has not been enough because it addresses the neurobiological dimension of depression and trauma that purely psychological interventions may not be able to reach in patients with entrenched, severe, or treatment-resistant presentations. When depression has a significant biological component, the prefrontal circuit disruption and synaptic density loss that characterize chronic depression may be an active barrier to therapeutic engagement: patients trying to do CBT or EMDR while severely depressed may lack the neurological substrate needed for the cognitive flexibility, emotional processing, and memory reconsolidation that these therapies require. Ketamine's rapid synaptogenesis restores prefrontal circuit function and creates a neuroplastic state that makes therapeutic work more accessible and productive, effectively using the treatment as a biological preparation for deeper psychological healing. For patients near Moment of Clarity who have worked hard in therapy without achieving the change they hoped for, this neurobiological bridge is the clinical reason ketamine-assisted therapy can succeed where therapy alone has not. Call 949-625-0564.

After a ketamine session, patients often experience a range of emotional states that can vary from profound relief and lightness to emotional vulnerability, heightened sensitivity, or a raw emotional quality that differs from their usual baseline. These emotional shifts reflect the neuroplastic process initiated by the session and the temporary dissolution of the usual psychological defenses that ketamine produces, and are a sign that the treatment is having neurological effects rather than a sign of anything concerning. Some patients feel deeply peaceful and clear after sessions; others experience a surfacing of emotions that had been buried or numbed by depression, including grief, tenderness, or openness that can feel both unfamiliar and meaningful. The clinical team at Moment of Clarity provides aftercare instructions, including recommendations for a calm, low-stimulation environment in the hours after treatment, and integration therapy sessions are scheduled specifically to help patients make sense of and work with whatever arises emotionally after each ketamine experience. Patients are encouraged to contact the clinical team if they experience any distress that feels difficult to manage in the hours following a session.

Ketamine-assisted therapy compares very favorably to traditional antidepressants in specific important dimensions, particularly speed of onset, response rate in treatment-resistant populations, and magnitude of antidepressant effect. Research data cited on the Moment of Clarity site shows ketamine demonstrates a very large effect size of approximately 1.5 compared to traditional antidepressants at approximately 0.3, emphasizing its powerful impact on depressive symptoms. Among patients completing all six infusions in a typical IV course, approximately 70.6% respond and 32.4% achieve remission. Traditional antidepressants typically show effect sizes of 0.3 to 0.5 and are far less effective in treatment-resistant populations where their response rates decline with each successive failed trial. The critical difference is context: ketamine therapy is most powerful for treatment-resistant and acute presentations, while traditional antidepressants remain the appropriate first-line pharmacological approach for patients who have not yet tried medication. For patients where antidepressants have failed, the data strongly favor exploring ketamine options at Moment of Clarity.

Set and setting, meaning the patient's mindset and the physical and social environment in which ketamine is administered, play a significant role in shaping the quality and therapeutic value of the ketamine experience, a principle drawn from the broader research on psychedelic-assisted therapy that applies to ketamine given its dissociative and altered-state-producing properties. A calm, comfortable, aesthetically considered clinical environment with appropriate lighting, music, and physical comfort reduces anxiety and supports a more open, exploratory internal experience during sessions. The therapeutic relationship and the patient's sense of trust in and safety with their clinical team is one of the most important set factors, as patients who feel genuinely held and supported are better able to approach vulnerable emotional material during the ketamine experience. Preparation sessions help shape set by clarifying intentions, addressing fears, and building a psychological framework for the experience that supports therapeutic rather than avoidant responses to what arises. Moment of Clarity's clinical environments are designed with patient comfort and clinical safety in mind, and the therapeutic relationship is cultivated across the full preparation, administration, and integration sequence. Call 949-625-0564.

Ketamine-assisted therapy at Moment of Clarity is primarily offered for adults, and the clinical evaluation for any adolescent patient would involve careful assessment of the risk-benefit balance, the specific FDA approval status of the treatment form being considered, and the clinical necessity given the adolescent's treatment history. Spravato (esketamine) is FDA-approved for adults 18 and older with treatment-resistant depression and MDD with suicidal ideation, and is not currently FDA-approved for pediatric or adolescent use. Off-label use of IV ketamine in adolescents has been described in the research literature for specific high-need presentations, but this is not standard practice and involves additional ethical and clinical considerations beyond adult use. For adolescents dealing with depression, PTSD, or anxiety, Moment of Clarity's evidence-based outpatient programming including CBT, DBT, and trauma-informed care represents the appropriate first-line approach, and TMS has received FDA clearance for adolescents aged 15 and older with MDD as an adjunct treatment. Any parent or caregiver seeking evaluation for an adolescent with treatment-resistant depression or other complex mental health presentations can call 949-625-0564 to discuss what options are appropriate and available.